Lercanidipine effect on circulating CD34+ progenitor cells in elderly patients: a randomized study

Area of Science:

• Cardiovascular Research
• Pharmacology
• Cell Biology

Background:

• Hypertension is a major risk factor for cardiovascular disease.
• Endothelial progenitor cells (EPCs) play a crucial role in vascular repair and endothelial function.
• Reduced EPC levels are associated with increased cardiovascular risk.

Purpose of the Study:

• To evaluate the effect of lercanidipine on circulating endothelial progenitor cells (EPCs) in elderly hypertensive patients.
• To assess the antihypertensive efficacy of lercanidipine.
• To determine if lercanidipine's effect on EPCs is independent of its blood pressure-lowering effect.

Main Methods:

• Randomized controlled study involving 61 elderly hypertensive patients.
• Patients were assigned to receive either lercanidipine 10 mg/day or other antihypertensive treatments (control group).
• Circulating EPCs were quantified using cytometry analysis at baseline, 12 weeks, and 24 weeks.

Main Results:

• Lercanidipine treatment led to a significant increase in circulating EPCs after 12 weeks, sustained throughout 24 weeks.
• The control group showed stable EPC numbers throughout the study.
• Both groups achieved significant blood pressure reduction at 12 weeks, with a negative correlation between systolic blood pressure and EPC numbers.

Conclusions:

• Lercanidipine may enhance EPC concentration in elderly hypertensive patients.
• The increase in EPCs appears to be independent of lercanidipine's antihypertensive effect.
• Further research with larger cohorts and longer follow-up is warranted to confirm these findings.